Fractyl Health (GUTS) EBT Margin (2023 - 2024)
Fractyl Health's (GUTS) quarterly EBT Margin came in at 853966.67% in Q4 2024, down 66639524.0% YoY from N/an in Q1 2024, and down 45.09% on a QoQ basis from 588592.86% in Q3 2024.
Fractyl Health (GUTS) EBT Margin (2023 - 2024) Analysis & Trends
Fractyl Health (GUTS) has 2 years of EBT Margin data on file, last reported at 853966.67% in Q4 2024.
- Quarterly EBT Margin fell 66639524.0% year-over-year to 853966.67% in Q4 2024, while the trailing twelve-month figure through Dec 2024 was 232937.63% (down 19111430.0% YoY) and the FY2024 annual result came in at 224954.84%, down 10344234.0% from the prior year.
- EBT Margin declined to 853966.67% in Q4 2024, from 588592.86% in the prior quarter.
- In the past five years, EBT Margin ranged from a high of 16279.17% in Q2 2023 to a low of 853966.67% in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 41.75% |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 35.61% |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 35.71% |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -528.97% |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 18.33% |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 13.77% |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -2.67% |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 12.09% |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -25.06% |
| 10 | Fractyl Health | 109.12 Mn | 109.12 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -853,966.67% |
| Sep 30, 2024 | -588,592.86% |
| Jun 30, 2024 | -191,925.58% |
| Mar 31, 2024 | -79,036.36% |
| Dec 31, 2023 | -187,571.43% |
| Sep 30, 2023 | -37,908.33% |
| Jun 30, 2023 | -16,279.17% |
| Mar 31, 2023 | -233,800.00% |